Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer (CTC-MBC)
2020年5月20日 更新者:Lund University Hospital
Women with metastatic breast cancer, receiving first line treatment of any kind (chemotherapy, endocrine treatment or treatment with antibodies) will be included in this trial.
In connection to treatment, blood samples for determination and enumeration of circulating tumour cells will be collected at different time points.
Serum and plasma will be collected and stored for future analysis of RNA and DNA.
研究概览
地位
完全的
条件
研究类型
观察性的
注册 (实际的)
150
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Lund、瑞典、221 85
- Lund University Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
女性
取样方法
概率样本
研究人群
Women with metastatic breast cancer
描述
Inclusion Criteria:
- Women with metastatic breast cancer
- ECOG performance status 0-2
- Age over18 years
- Signed informed concent
- Predicted life expectancy over 2 months
- Planned for first line systemic treatment for metastatic disease (chemotherapy, antibody treatment or endocrine treatment)
- Standard imaging evaluation within 4 weeks of inclusion
- Planned for standard imaging within 16 weeks after start of therapy
Exclusion Criteria:
- Prior medical therapy for metastatic disease (prior adjuvant chemotherapy, radiotherapy or endocrine therapy is permitted)
- Inability to understand information about the study
- Other malignant disease with the exception of curatively treated basal cell or squamous cell cancer of the skin and cancer in situ of the cervix
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 观测模型:其他
- 时间观点:预期
队列和干预
团体/队列 |
---|
Blood sampling.
Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
To determine whether numbers of circulating tumour cells in peripheral blood can give information of prognosis, and to evaluate if the numbers of circulating tumour cells can give information of the efficacy of given treatment
大体时间:Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
|
Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Narbe U, Bendahl PO, Aaltonen K, Ferno M, Forsare C, Jorgensen CLT, Larsson AM, Ryden L. The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breast-Long-Term Prognostic Significance. Cells. 2020 Jul 17;9(7):1718. doi: 10.3390/cells9071718.
- Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer Jorgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K, Ryden L. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018 Jun 8;20(1):48. doi: 10.1186/s13058-018-0976-0.
- Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Ryden L. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016 Jul 8;16:433. doi: 10.1186/s12885-016-2406-y.
- Frithiof H, Welinder C, Larsson AM, Ryden L, Aaltonen K. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. J Transl Med. 2015 Apr 21;13:126. doi: 10.1186/s12967-015-0493-1.
有用的网址
- A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. - PubMed - NCBI
- Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospec... - PubMed - NCBI
- A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation. - PubMed - NCBI
- Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells.
- Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer.
- Longitudinal CTC and CTC-cluster evaluation improves prognostication and monitoring in metastatic breast cancer patients during 1st line systemic treatment.
- Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
- Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.
- A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation.
- A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2011年3月1日
初级完成 (实际的)
2016年6月1日
研究完成 (实际的)
2016年6月1日
研究注册日期
首次提交
2011年3月24日
首先提交符合 QC 标准的
2011年3月24日
首次发布 (估计)
2011年3月25日
研究记录更新
最后更新发布 (实际的)
2020年5月22日
上次提交的符合 QC 标准的更新
2020年5月20日
最后验证
2019年5月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.